Stock AnalizGRAIL, Inc. GRAL
Medical Specialities · data as of November 13, 2026
GRAIL, Inc. (GRAL) is a healthcare company listed in the US with a market value of about $5.2B. In the twelve months to September 30, 2026 it had revenue of $167M and net income of -$406M, a net margin of -243.8%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -48%.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $167M | $147M | $126M | $93M | $56M |
| Net income | -$406M | -$408M | -$2.0B | -$1.5B | -$5.4B |
| Free cash flow | -$312M | -$300M | -$582M | -$609M | -$584M |
| EPS (diluted) | $-9.44 | $-11.11 | $-63.54 | $-47.21 | $-173.89 |
| Net margin | -243.8% | -277.5% | -1613.9% | -1574.2% | -9719.4% |
| ROIC | — | -16.3% | -79.8% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $139.44, 20% above the current price; targets range from $100.00 to $175.00; the consensus rating is “Buy”; expected EPS is $-5.75 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does GRAIL pay a dividend?
Not currently.
Is GRAIL a good stock to buy?
We do not give buy or sell advice. GRAIL scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.